AbbVie stock falls as technical overbought signals and insider transactions spark caution

Traders Union
All News
Financial News
AbbVie slides 3.04% to $229.00 today

Highlights

AbbVie raised about $8 billion through a multi-tranche public notes offering to enhance balance sheet flexibility for pipeline investments and acquisitions.
Positive Phase 3 data for SKYRIZI in Crohn's disease and advancement of venetoclax support AbbVie's R&D momentum despite recent insider selling.
ABBV is forecast to trade between $220 and $234 as bullish momentum persists, but overbought conditions and intraday pressure signal possible near-term consolidation.

Capital raising and insider sales as drug pipeline momentum meets selling pressure

On March 4, 2026, AbbVie completed an underwritten public notes offering totaling between $7.75 billion and $8 billion, issuing a mix of senior floating rate notes and unsecured fixed-rate senior notes with maturities between 2028 and 2066. This action was intended to support the company's balance sheet and increase financial flexibility for investments in its drug pipeline as well as potential strategic transactions. Recent activity included significant stock sales by EVP and General Counsel Perry C. Siatis on March 2 and March 3, 2026. AbbVie also reported positive topline Phase 3 results from the AFFIRM trial of risankizumab (SKYRIZI) in Crohn’s disease and advanced a Phase 2 study of venetoclax in Japan, though price action has remained under broader selling pressure.

Overbought signals and weak trend momentum as downside reversal risk emerges

MACD signals ongoing buy momentum, but the low ADX reading indicates the current trend is weak. Oscillators highlight overbought conditions, with RSI elevated at 62.38 and signaling a buy, Stochastic RSI extremely overbought, and the Commodity Channel Index also positioned in overbought territory. Bull/Bear Power remains positive and in overbought territory, reflecting continued buyer dominance. However, the daily decline of 3.04% and a downside price gap signal a possible intraday reversal, with ABBV hovering near the session lows and showing signs of momentum/oscillator divergence. Technical support lies around $220.63 (Ichimoku Kijun) and a broad support area at $220, with short-term resistance at $234.

Range-bound outlook as technicals favor upside consolidation within key band

In the coming week, ABBV is expected to oscillate in a typical volatility band between $220 and $234. Short-term technicals and weekly indicators suggest a greater than 80% probability of further price increases, making a decline less likely in the immediate term. The baseline outlook is for sideways consolidation within this range. A breakout above $234 would confirm renewed buying control, while a pullback below $220 could trigger additional selling pressure.

Anton Kharitonov, expert at Traders Union, sees ABBV sitting above key moving averages, which suggests bullish structure, but cautions that momentum is fading. He notes that despite the large notes offering and positive Phase 3 trial news, technical indicators are overbought and price action is under pressure. Kharitonov believes price will consolidate between $220 and $234, with the immediate risk of a reversal if support fails. "Until $220 breaks decisively, my base case is for choppy, sideways movement and a defensive posture."

Previously it was reported that AbbVie Inc. is trading above key short-, medium-, and long-term moving averages, maintaining a bullish structure despite heightened volatility and mixed momentum signals; daily indicators like MACD and RSI remain positive, but intraday readings reflect strong downside pressure and overbought conditions. Institutional activity and positive drug trial news provide fundamental support, though near-term technical resistance is evident, and a drop below current short-term support could trigger further losses.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.